Open-label risperidone for Asperger's disorder

Negative symptom spectrum response

Jeffrey L. Rausch, Elizabeth L. Sirota, Donna Lynn Londino, Maria E. Johnson, Benjamin M. Carr, Renu Bhatia, Stephen Miller

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Asperger's disorder consists of negative symptoms similar to those seen in schizophrenia, autism, schizoid personality disorder, and schizotypal personality disorder. We investigated whether risperidone, which is effective in treating the negative symptoms of schizophrenia, would improve such symptoms observed in Asperger's disorder in a prospective, open-label trial. Method: Thirteen male patients aged 6 to 18 years who were diagnosed with Asperger's disorder by DSM-IV criteria were enrolled in a 12-week, prospective, open-label pilot study from March 13, 2002 to August 11, 2003. All subjects were started on risperidone 0.25 mg twice per day. Doses were increased based on clinical indication and tolerability. The primary efficacy variable was the Scale for the Assessment of Negative Symptoms (SANS). Each subject's baseline score served as his control. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Montgomery-Asberg Depression Rating Scale, Global Assessment Scale, and a modified Asperger Syndrome Diagnostic Scale. Results: We found a statistically significant improvement from baseline for last-observation-carried-forward (LOCF) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, SANS scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for LOCF). We also found statistically significant improvement in all secondary efficacy measurements (F values range, 8.41 to 15.73, p values range, < .0001 to < .005 for 12-week completers; F values range, 6.53 to 7.75, all p < .0001 for LOCF). Conclusions: Subjects' symptoms significantly improved after risperidone. The open-label nature of this small pilot study suggests caution in interpreting these data, but the results suggest that placebo-controlled trials should follow.

Original languageEnglish (US)
Pages (from-to)1592-1597
Number of pages6
JournalJournal of Clinical Psychiatry
Volume66
Issue number12
DOIs
StatePublished - Jan 1 2005

Fingerprint

Asperger Syndrome
Risperidone
Symptom Assessment
Observation
Schizophrenia
Schizoid Personality Disorder
Schizotypal Personality Disorder
Brief Psychiatric Rating Scale
Autistic Disorder
Diagnostic and Statistical Manual of Mental Disorders
Placebos
Outcome Assessment (Health Care)
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Rausch, J. L., Sirota, E. L., Londino, D. L., Johnson, M. E., Carr, B. M., Bhatia, R., & Miller, S. (2005). Open-label risperidone for Asperger's disorder: Negative symptom spectrum response. Journal of Clinical Psychiatry, 66(12), 1592-1597. https://doi.org/10.4088/JCP.v66n1216

Open-label risperidone for Asperger's disorder : Negative symptom spectrum response. / Rausch, Jeffrey L.; Sirota, Elizabeth L.; Londino, Donna Lynn; Johnson, Maria E.; Carr, Benjamin M.; Bhatia, Renu; Miller, Stephen.

In: Journal of Clinical Psychiatry, Vol. 66, No. 12, 01.01.2005, p. 1592-1597.

Research output: Contribution to journalArticle

Rausch, JL, Sirota, EL, Londino, DL, Johnson, ME, Carr, BM, Bhatia, R & Miller, S 2005, 'Open-label risperidone for Asperger's disorder: Negative symptom spectrum response', Journal of Clinical Psychiatry, vol. 66, no. 12, pp. 1592-1597. https://doi.org/10.4088/JCP.v66n1216
Rausch, Jeffrey L. ; Sirota, Elizabeth L. ; Londino, Donna Lynn ; Johnson, Maria E. ; Carr, Benjamin M. ; Bhatia, Renu ; Miller, Stephen. / Open-label risperidone for Asperger's disorder : Negative symptom spectrum response. In: Journal of Clinical Psychiatry. 2005 ; Vol. 66, No. 12. pp. 1592-1597.
@article{7f90196b32ba470c89e05cf71e5a723a,
title = "Open-label risperidone for Asperger's disorder: Negative symptom spectrum response",
abstract = "Objective: Asperger's disorder consists of negative symptoms similar to those seen in schizophrenia, autism, schizoid personality disorder, and schizotypal personality disorder. We investigated whether risperidone, which is effective in treating the negative symptoms of schizophrenia, would improve such symptoms observed in Asperger's disorder in a prospective, open-label trial. Method: Thirteen male patients aged 6 to 18 years who were diagnosed with Asperger's disorder by DSM-IV criteria were enrolled in a 12-week, prospective, open-label pilot study from March 13, 2002 to August 11, 2003. All subjects were started on risperidone 0.25 mg twice per day. Doses were increased based on clinical indication and tolerability. The primary efficacy variable was the Scale for the Assessment of Negative Symptoms (SANS). Each subject's baseline score served as his control. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Montgomery-Asberg Depression Rating Scale, Global Assessment Scale, and a modified Asperger Syndrome Diagnostic Scale. Results: We found a statistically significant improvement from baseline for last-observation-carried-forward (LOCF) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, SANS scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for LOCF). We also found statistically significant improvement in all secondary efficacy measurements (F values range, 8.41 to 15.73, p values range, < .0001 to < .005 for 12-week completers; F values range, 6.53 to 7.75, all p < .0001 for LOCF). Conclusions: Subjects' symptoms significantly improved after risperidone. The open-label nature of this small pilot study suggests caution in interpreting these data, but the results suggest that placebo-controlled trials should follow.",
author = "Rausch, {Jeffrey L.} and Sirota, {Elizabeth L.} and Londino, {Donna Lynn} and Johnson, {Maria E.} and Carr, {Benjamin M.} and Renu Bhatia and Stephen Miller",
year = "2005",
month = "1",
day = "1",
doi = "10.4088/JCP.v66n1216",
language = "English (US)",
volume = "66",
pages = "1592--1597",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "12",

}

TY - JOUR

T1 - Open-label risperidone for Asperger's disorder

T2 - Negative symptom spectrum response

AU - Rausch, Jeffrey L.

AU - Sirota, Elizabeth L.

AU - Londino, Donna Lynn

AU - Johnson, Maria E.

AU - Carr, Benjamin M.

AU - Bhatia, Renu

AU - Miller, Stephen

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objective: Asperger's disorder consists of negative symptoms similar to those seen in schizophrenia, autism, schizoid personality disorder, and schizotypal personality disorder. We investigated whether risperidone, which is effective in treating the negative symptoms of schizophrenia, would improve such symptoms observed in Asperger's disorder in a prospective, open-label trial. Method: Thirteen male patients aged 6 to 18 years who were diagnosed with Asperger's disorder by DSM-IV criteria were enrolled in a 12-week, prospective, open-label pilot study from March 13, 2002 to August 11, 2003. All subjects were started on risperidone 0.25 mg twice per day. Doses were increased based on clinical indication and tolerability. The primary efficacy variable was the Scale for the Assessment of Negative Symptoms (SANS). Each subject's baseline score served as his control. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Montgomery-Asberg Depression Rating Scale, Global Assessment Scale, and a modified Asperger Syndrome Diagnostic Scale. Results: We found a statistically significant improvement from baseline for last-observation-carried-forward (LOCF) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, SANS scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for LOCF). We also found statistically significant improvement in all secondary efficacy measurements (F values range, 8.41 to 15.73, p values range, < .0001 to < .005 for 12-week completers; F values range, 6.53 to 7.75, all p < .0001 for LOCF). Conclusions: Subjects' symptoms significantly improved after risperidone. The open-label nature of this small pilot study suggests caution in interpreting these data, but the results suggest that placebo-controlled trials should follow.

AB - Objective: Asperger's disorder consists of negative symptoms similar to those seen in schizophrenia, autism, schizoid personality disorder, and schizotypal personality disorder. We investigated whether risperidone, which is effective in treating the negative symptoms of schizophrenia, would improve such symptoms observed in Asperger's disorder in a prospective, open-label trial. Method: Thirteen male patients aged 6 to 18 years who were diagnosed with Asperger's disorder by DSM-IV criteria were enrolled in a 12-week, prospective, open-label pilot study from March 13, 2002 to August 11, 2003. All subjects were started on risperidone 0.25 mg twice per day. Doses were increased based on clinical indication and tolerability. The primary efficacy variable was the Scale for the Assessment of Negative Symptoms (SANS). Each subject's baseline score served as his control. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Montgomery-Asberg Depression Rating Scale, Global Assessment Scale, and a modified Asperger Syndrome Diagnostic Scale. Results: We found a statistically significant improvement from baseline for last-observation-carried-forward (LOCF) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, SANS scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for LOCF). We also found statistically significant improvement in all secondary efficacy measurements (F values range, 8.41 to 15.73, p values range, < .0001 to < .005 for 12-week completers; F values range, 6.53 to 7.75, all p < .0001 for LOCF). Conclusions: Subjects' symptoms significantly improved after risperidone. The open-label nature of this small pilot study suggests caution in interpreting these data, but the results suggest that placebo-controlled trials should follow.

UR - http://www.scopus.com/inward/record.url?scp=30344437027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344437027&partnerID=8YFLogxK

U2 - 10.4088/JCP.v66n1216

DO - 10.4088/JCP.v66n1216

M3 - Article

VL - 66

SP - 1592

EP - 1597

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12

ER -